

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A Peptide ~~comprising~~ consisting of the sequence of amino acids selected from:

- the sequence 13-39 of the HARP factor ; and
- the sequence 65-97 of the HARP factor.

2. (previously presented) A Peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID NO: 2 or SEQ ID NO: 3, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).

3. (previously presented) The Peptide according to Claim 2, in which the sequence differs from the sequence SEQ ID NO: 2 or SEQ ID NO: 3 by the conservative substitution of at least one amino acid.

4. (previously presented) A Nucleic acid comprising a sequence coding for a peptide according to claim 1.

5. (previously presented) The Nucleic acid according to Claim 4, comprising the sequence SEQ ID NO: 5 or SEQ ID NO: 6.

6. (previously presented) A Method of production of a peptide according to claim 1, comprising the synthesis of the said peptide by chemical means.

7. (previously presented) A Method of production of a peptide according to claim 1, in which a vector containing a nucleic acid that encodes said peptide is transferred into a host cell which is cultured under conditions permitting the expression of the corresponding peptide.

8. (previously presented) A Pharmaceutical composition comprising a peptide according to claim 1, and one or more pharmaceutically acceptable excipients.

9. (previously presented) The Composition according to Claim 8, further comprising a peptide having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

10. (previously presented) The Composition according to Claim 9, comprising :

- a. the peptide 13-39 of sequence SEQ ID NO: 2 ;
- b. the peptide 65-97 of sequence SEQ ID NO: 3 ; et
- c. the peptide 111-136 of sequence SEQ ID NO: 4.

11. (previously presented) A Pharmaceutical composition comprising a nucleic acid comprising a sequence encoding for a peptide as according to claim 1.

12. (previously presented) The Composition according to Claim 11, further comprising a nucleic acid comprising a sequence encoding for a peptide having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80% similar to the sequence of SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

13. (previously presented) The Composition according to Claim 12, comprising :

- a nucleic acid coding for the peptide 13-39 of sequence SEQ ID NO: 2 ;
- a nucleic acid coding for the peptide 65-97 of sequence SEQ ID NO: 3 ;
- a nucleic acid coding for the peptide 111-136 of sequence SEQ ID NO: 4.

14. (currently amended) The Composition according to Claim 12 ~~or 13~~, in which the said nucleic acids are carried by one single vector.

15. (previously presented) A method for the preparation of a medicament for the treatment of a pathology associated with an angiogenesis , comprising adding the peptide according to claim 1 to a pharmaceutically acceptable vehicle.

16. (previously presented) The method according to claim 15, wherein said peptide associated with a second peptide having the sequence of amino acids 111-136 of the HARP factor or with a peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

17. (previously presented) A method for the preparation of a medicament intended for the treatment of a pathology associated with an angiogenesis , comprising adding a nucleic acid according to claim 4 to said medicament.

18. (previously presented) The method according to Claim 17, in which the nucleic acid is associated with a nucleic acid comprising a sequence encoding for a peptide having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80% similar to the sequence of SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

19. (previously presented) The method according to claim 15, in which the pathology is a tumour, an ocular lesion, rheumatoid polyarthrititis or a skin disease.